MHRA Threat to clinics In communication with the MHRA, they also stated: However, we do have concerns about the level of clinical oversight present in IV vitamin therapy and injection services in general and the appropriacy of such services is currently under review. This review, if deciding on stopping treatment of B12 injections by clinics who do comply with the ridiculous rules of the MHRA, would not only negatively impact the companies and individuals who give B12 injections, but also to the people who rely on them to keep functioning both physically and mentally

In the first year following diagnosis, we found increased cumulative incidence risk ratios in a number of outcomes including: - Any mental, behavioural, or neurodevelopmental disorder 1.96 (1.93 - 1.99) - Postpartum depression 2.70 (2.61 - 2.79) - Eating disorders 2.06 (1.85 - 2.89) - PTSD 1.77 (1.69 - 1.86) We also saw significantly increased risk in rare but serious outcomes such as: - Wernicke's encephalopathy 2.39 (1.25 - 4.56) - Puerperal psychosis 1.80 (1.48 - 2.20) Interestingly, cases of hyperemesis gravidarum with metabolic disturbance displayed a significantly lower risk of any depression and postpartum depression compared with those without metabolic disturbance
There is one BPC-157 option: a 5 mg vial priced at $59.99
Well-tolerated with minimal side effects in studies and trials
Stress may also make the symptoms worse, but it doesnt cause them
Medically Reviewed By: Karla K